JP2005516978A - 光増感剤および光のピーク波長を使用する血液および血液製剤中の汚染の減少 - Google Patents
光増感剤および光のピーク波長を使用する血液および血液製剤中の汚染の減少 Download PDFInfo
- Publication number
- JP2005516978A JP2005516978A JP2003563604A JP2003563604A JP2005516978A JP 2005516978 A JP2005516978 A JP 2005516978A JP 2003563604 A JP2003563604 A JP 2003563604A JP 2003563604 A JP2003563604 A JP 2003563604A JP 2005516978 A JP2005516978 A JP 2005516978A
- Authority
- JP
- Japan
- Prior art keywords
- light
- photosensitizer
- liquid
- processing chamber
- support platform
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 79
- 239000010836 blood and blood product Substances 0.000 title claims abstract description 23
- 238000011109 contamination Methods 0.000 title description 4
- 239000007788 liquid Substances 0.000 claims abstract description 82
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 47
- 244000052769 pathogen Species 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 35
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000019192 riboflavin Nutrition 0.000 claims abstract description 24
- 239000002151 riboflavin Substances 0.000 claims abstract description 24
- 229940125691 blood product Drugs 0.000 claims abstract description 22
- 229960002477 riboflavin Drugs 0.000 claims abstract description 22
- 239000012530 fluid Substances 0.000 claims abstract description 5
- 230000005855 radiation Effects 0.000 claims description 67
- 238000012545 processing Methods 0.000 claims description 47
- 210000003743 erythrocyte Anatomy 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 9
- 230000001678 irradiating effect Effects 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 230000033001 locomotion Effects 0.000 claims description 7
- 230000000415 inactivating effect Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 125000001452 riboflavin group Chemical group 0.000 claims description 3
- 238000002211 ultraviolet spectrum Methods 0.000 claims 2
- 230000002779 inactivation Effects 0.000 abstract description 8
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 239000012503 blood component Substances 0.000 description 9
- 230000002147 killing effect Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 8
- 244000005700 microbiome Species 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000000862 absorption spectrum Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- HAUGRYOERYOXHX-UHFFFAOYSA-N Alloxazine Chemical compound C1=CC=C2N=C(C(=O)NC(=O)N3)C3=NC2=C1 HAUGRYOERYOXHX-UHFFFAOYSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000008212 P-Selectin Human genes 0.000 description 4
- 108010035766 P-Selectin Proteins 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- KPDQZGKJTJRBGU-UHFFFAOYSA-N lumiflavin Chemical compound CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O KPDQZGKJTJRBGU-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- ZJTJUVIJVLLGSP-UHFFFAOYSA-N lumichrome Chemical class N1C(=O)NC(=O)C2=C1N=C1C=C(C)C(C)=CC1=N2 ZJTJUVIJVLLGSP-UHFFFAOYSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000906 photoactive agent Substances 0.000 description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical group CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004103 aerobic respiration Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- PPBOKXIGFIBOGK-BDTUAEFFSA-N bvdv Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)C(C)C)[C@@H](C)CC)C1=CN=CN1 PPBOKXIGFIBOGK-BDTUAEFFSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 238000006303 photolysis reaction Methods 0.000 description 2
- 230000015843 photosynthesis, light reaction Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QEUYATCJHJUQML-UHFFFAOYSA-N acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride;hydrochloride Chemical compound Cl.[Cl-].C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21.C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 QEUYATCJHJUQML-UHFFFAOYSA-N 0.000 description 1
- 229940002707 acriflavine hydrochloride Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229910052736 halogen Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 108010058237 plasma protein fraction Proteins 0.000 description 1
- 229940081857 plasma protein fraction Drugs 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000013214 routine measurement Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/0047—Ultraviolet radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/0076—Radiation using a photocatalyst or photosensitiser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/24—Apparatus using programmed or automatic operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/26—Accessories or devices or components used for biocidal treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/22—Blood or products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
- A61M2205/053—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy ultraviolet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Description
HIV、肝炎、およびその他のウイルス、並びに細菌などの感染性の微生物による全血または血液製剤の汚染は、全血の輸血または以下のものなどの種々の血液製剤もしくは血液成分の投与を受けなければならないものにとって深刻な健康上の害が存在する:血小板、赤血球、血漿、第VIII因子、プラスミノーゲン、フィブロネクチン、抗トロンビンIII、クリオプレシピテート、ヒト血漿タンパク質分画、アルブミン、免疫血清グロブリン、プロトロンビン複合体血漿成長ホルモン、および血液から単離されるその他の成分。血液スクリーニング法では、病原性の汚染を逃してしまうかもしれず、細胞の血液成分にダメージを与えずに、全ての感染性ウイルスおよびその他の微生物を効率的に不活化する滅菌法は、これまで利用できなかった。
本発明は、光能動的な薬剤と共に、血液製剤および病原体を含む液体を照射するための方法および装置を提供する。液体中に含まれるあらゆる病原体を不活化するために、光能動的な薬剤を活性化するように、並びに特定の血液製剤を含む液体を透過するように選ばれたピーク波長を有する光に液体を曝露する。
「血液製剤」の用語は、本明細書に使用されるものとして、上記の通りに血液に由来するタンパク質を含む全ての血液成分または血液構成成分を含む。また、血液に由来するもの以外の生物学的に活性なタンパク質を含む液体を、本発明の方法および装置よって処理してもよい。
Claims (38)
- 赤血球を含む液体中の病原体を不活化するための方法であって;
前記液体に光増感剤を添加して混合物を形成することと、および、
前記液体および前記光増感剤の混合物を約470nmのピーク波長を有する光に曝露することと、
を含む方法。 - 前記曝露する工程が光をパルスにすることをさらに含む、請求項1に記載の方法。
- 前記光増感剤が内因性の光増感剤である、請求項1に記載の方法。
- 前記光増感剤がイソアロキサジンである、請求項1に記載の方法。
- 前記光増感剤がリボフラビンである、請求項1に記載の方法。
- 血小板を含む液体中の病原体を不活化するための方法であって;
前記液体に光増感剤を添加して混合物を形成することと、および、
前記液体および前記光増感剤の混合物を約305〜313nmの間の範囲内の光に曝露することと、
を含む方法。 - 前記曝露する工程が前記混合物を308nmのピーク波長を有する光に曝露することをさらに含む、請求項6に記載の方法。
- 前記曝露する工程が前記混合物をピーク波長のパルスにされた光に曝露することをさらに含む、請求項6に記載の方法。
- 前記光増感剤が内因性の光増感剤である、請求項6に記載の方法。
- 前記光増感剤がイソアロキサジンである、請求項6に記載の方法。
- 前記光増感剤がリボフラビンである、請求項6に記載の方法。
- 赤血球および光増感剤を含む液体中の病原体を不活化するための処理チャンバであって:
約470nmのピーク波長で放射を放射する少なくとも1つの放射放射源;
照射される赤血球および光増感剤を含む前記液体を保持するための支持プラットフォーム;および、
前記放射放射源を制御するための制御装置、
を含む処理チャンバ。 - 前記放射放射源がパルスにすることができる、請求項12に記載の処理チャンバ。
- 前記支持プラットフォームが処理チャンバ内で多方向に移動することができる、請求項12に記載の処理チャンバ。
- 前記制御装置がさらに前記支持プラットフォームの前記移動を制御する、請求項14に記載の処理チャンバ。
- 前記支持プラットフォームが光透過性の材料でできている、請求項12に記載の処理チャンバ。
- 前記チャンバが少なくとも1つの反射面をさらに含む、請求項12に記載の処理チャンバ。
- 前記支持プラットフォームが反射面を含む、請求項12に記載の処理チャンバ。
- 前記放射放射源が複数の別々の光を含むアレイをさらに含む、請求項12に記載の処理チャンバ。
- 前記複数の別々の光を含むアレイが複数のLEDをさらに含む、請求項19に記載に記載の処理チャンバ。
- 前記複数のLEDが青である、請求項20に記載の処理チャンバ。
- 前記制御装置が前記放射パルスと協調して前記支持プラットフォームをさらに移動する、請求項13に記載の処理チャンバ。
- 赤血球および光増感剤を含む液体中の病原体を不活化するための処理チャンバであって:
約308nmのピーク波長で放射を放射する少なくとも1つの放射放射源;
照射される赤血球および光増感剤を含む前記液体を保持するための支持プラットフォーム;および、
前記放射放射源を制御するための制御装置、
を含む処理チャンバ。 - 前記放射放射源がパルスにすることができる、請求項23に記載の処理チャンバ。
- 前記支持プラットフォームが処理チャンバ内で多方向に移動することができる、請求項23に記載の処理チャンバ。
- 前記制御装置が前記支持プラットフォームの前記移動をさらに制御する、請求項25に記載の処理チャンバ。
- 前記支持プラットフォームが光透過性の材料でできている、請求項23に記載の処理チャンバ。
- 前記チャンバが少なくとも1つの反射面をさらに含む、請求項23に記載の処理チャンバ。
- 前記支持プラットフォームが反射面でできている、請求項23に記載の処理チャンバ。
- 前記制御装置が前記放射パルスと協調して前記支持プラットフォームをさらに移動する、請求項24に記載の処理チャンバ。
- 請求項6に記載の方法であって:
305〜313nmの間の範囲の光を除く全ての光をフィルタリングすること、
をさらに含む方法。 - 前記フィルタリング工程が約308nmのピーク波長を有する光を除くUVスペクトルの全ての光を除去することを含む、請求項31に記載の方法。
- 前記フィルタリング工程が約313nmのピーク波長を有する光を除くUVスペクトルの全ての光を除去することを含む、請求項31に記載の方法。
- 請求項1に記載の方法であって;
前記曝露する工程の間に前記液体および光増感剤を混合して前記液体の大部分を光に曝露すること、
をさらに含む方法。 - 光がパルスにされた光である、請求項6に記載の方法。
- 以下の工程を含む、血小板を含む液体を照射する方法:
前記液体に、前記液体中に含まれるあらゆる病原体を不活化するために必要な光増感剤の量を添加することと;
約308nmの波長の光に前記液体および光増感剤を曝露することと;および、
前記曝露する工程の間に前記液体および光増感剤を混合して前記液体の大部分を光に曝露すること。 - 以下の工程を含む、光透過性のバッグ内に含まれる液体中の赤血球に照射する方法:
前記バッグに、液体中に含まれるあらゆる病原体を不活化するために必要な量のリボフラビンを添加することと;
少なくとも前記液体およびリボフラビンを含む前記バッグを、光のピーク波長に曝露することと;および、
前記曝露する工程の間に前記バッグの内容物を混合すること。 - 以下の工程を含む、血液製剤に照射する方法:
a)前記血液製剤に含まれるあらゆる病原体を不活化するために必要な光増感剤の量を添加することと;
b)約470nmの光のピーク波長を有する放射源パルスにして、前記血液製剤および光増感剤をピーク波長で放射に曝露することと;
c)放射源のパルスを止めて、放射に対する前記血液製剤および光増感剤の暴露を止めることと;
d)前記パルスを止める工程の間に前記血液製剤および光増感剤に放射源を調合することと;および、
e)工程b)、c)、およびd)を繰り返すこと。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35322302P | 2002-02-01 | 2002-02-01 | |
US60/353,223 | 2002-02-01 | ||
PCT/US2003/003359 WO2003063915A1 (en) | 2002-02-01 | 2003-02-03 | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005516978A true JP2005516978A (ja) | 2005-06-09 |
JP2005516978A5 JP2005516978A5 (ja) | 2005-12-22 |
JP4704684B2 JP4704684B2 (ja) | 2011-06-15 |
Family
ID=27663187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003563604A Expired - Lifetime JP4704684B2 (ja) | 2002-02-01 | 2003-02-03 | 光増感剤および光のピーク波長を使用する血液および血液製剤中の汚染の減少 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1469891B1 (ja) |
JP (1) | JP4704684B2 (ja) |
CA (1) | CA2474242C (ja) |
DE (1) | DE60327166D1 (ja) |
WO (1) | WO2003063915A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007004593A1 (ja) * | 2005-07-01 | 2007-01-11 | National University Corporation Okayama University | ビリルビン変性器及びビリルビン透析装置 |
JP2008161095A (ja) * | 2006-12-27 | 2008-07-17 | Univ Of Tokushima | 紫外線殺菌装置と紫外線殺菌方法 |
JP2009520703A (ja) * | 2005-12-23 | 2009-05-28 | ブルートシュペンデディーンスト デア ランデスフェアベンデ デス ドイチェン ローテン クロイツェス ニーダーザクセン,ザクセン−アンハルト,テューリンゲン,オルデンブルク ウント ブレーメン ゲーゲ | 給血者の血、血漿、または、赤血球濃縮物中の病原体を柔軟な容器中で動かしながら不活化するための方法 |
JP2010532214A (ja) * | 2007-07-02 | 2010-10-07 | カリディアンビーシーティ バイオテクノロジーズ,エルエルシー | 測定手段を用いて血液中および血液生成物中の汚染物質を光還元するための装置 |
JP2012528873A (ja) * | 2009-06-02 | 2012-11-15 | セラムオプテック インダストリーズ インコーポレーテッド | 抗菌性光力学治療を用いたヒト血液及び血液製剤における微生物枯渇のための新たな方法 |
JP2013517093A (ja) * | 2010-01-19 | 2013-05-16 | セラモプテック インダストリーズ,インコーポレイテッド | 増強された抗菌pdt |
WO2017164202A1 (ja) * | 2016-03-23 | 2017-09-28 | テルモ株式会社 | 光照射装置 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2689465C (en) | 2005-12-19 | 2012-10-02 | Lumen Associates, Inc. | Syringe for use with an apparatus for irradiation of fluid with electromagnetic radiation |
DE102005062410A1 (de) | 2005-12-23 | 2007-08-09 | Forschungsgemeinschaft Der Drk-Blutspendedienste E.V. | Verfahren zur Bestrahlung von Thrombozytenkonzentraten in flexiblen Behältnissen mit ultraviolettem Licht |
EP1902740A1 (en) * | 2006-09-19 | 2008-03-26 | Maco Pharma S.A. | Blood bag system and process for the inactivation of pathogens in platelet concentrates by use of the blood bag system |
EP2008669A1 (en) | 2007-06-22 | 2008-12-31 | Maco Pharma S.A. | Irradiation apparatus for inactivating pathogens and/or leukocytes in a biological fluid and process |
US20140127077A1 (en) | 2012-11-05 | 2014-05-08 | Gail Rock | Device and method for sterilization of instruments and surfaces |
WO2016054150A1 (en) * | 2014-09-30 | 2016-04-07 | Sensor Electronic Technology, Inc. | Movable ultraviolet radiation source |
CN104667364A (zh) * | 2015-02-11 | 2015-06-03 | 杨萌 | 混合光源光量子血液照射装置 |
WO2020023942A2 (en) | 2018-07-27 | 2020-01-30 | Terumo Bct Biotechnologies, Llc | Fluid flow-through |
US11896725B2 (en) * | 2020-05-20 | 2024-02-13 | Juladore Limited | Portable bag for sterilizing an object |
WO2021232462A1 (en) * | 2020-05-20 | 2021-11-25 | Juladore Limited | A portable bag for sterilizing an object |
CN114366831A (zh) * | 2022-01-10 | 2022-04-19 | 南京双威生物医学科技有限公司 | 一种基于核黄素光化学法的血浆病原体灭活处理方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001096340A1 (en) * | 2000-06-15 | 2001-12-20 | Gambro, Inc. | Method for inactivation of microorganisms using photosensitizers |
WO2002002152A1 (de) * | 2000-07-04 | 2002-01-10 | Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH | Photodynamische behandlung und uv-b- bestrahlung einer thrombozyten-suspension |
JP2005519920A (ja) * | 2002-02-01 | 2005-07-07 | ガンブロ インコーポレーテッド | 光増感剤を使用する西ナイルウイルスおよびマラリアの不活化 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3930510A1 (de) * | 1989-09-13 | 1991-03-21 | Blutspendedienst Dt Rote Kreuz | Verfahren zur inaktivierung von viren in blut und blutprodukten |
US6258577B1 (en) * | 1998-07-21 | 2001-07-10 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers |
WO2002026270A2 (en) * | 2000-09-27 | 2002-04-04 | Gambro, Inc. | Inactivation of contaminants using photosensitizers and pulsed light |
-
2003
- 2003-02-03 JP JP2003563604A patent/JP4704684B2/ja not_active Expired - Lifetime
- 2003-02-03 EP EP03706079A patent/EP1469891B1/en not_active Expired - Lifetime
- 2003-02-03 DE DE60327166T patent/DE60327166D1/de not_active Expired - Lifetime
- 2003-02-03 WO PCT/US2003/003359 patent/WO2003063915A1/en active Application Filing
- 2003-02-03 CA CA2474242A patent/CA2474242C/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001096340A1 (en) * | 2000-06-15 | 2001-12-20 | Gambro, Inc. | Method for inactivation of microorganisms using photosensitizers |
WO2002002152A1 (de) * | 2000-07-04 | 2002-01-10 | Blutspendedienst der Landesverbände des Deutschen Roten Kreuzes Niedersachsen, Sachsen-Anhalt, Thüringen, Oldenburg und Bremen gGmbH | Photodynamische behandlung und uv-b- bestrahlung einer thrombozyten-suspension |
JP2005519920A (ja) * | 2002-02-01 | 2005-07-07 | ガンブロ インコーポレーテッド | 光増感剤を使用する西ナイルウイルスおよびマラリアの不活化 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007004593A1 (ja) * | 2005-07-01 | 2007-01-11 | National University Corporation Okayama University | ビリルビン変性器及びビリルビン透析装置 |
JP2007007292A (ja) * | 2005-07-01 | 2007-01-18 | Okayama Univ | ビリルビン変性器及びビリルビン透析装置 |
US7998100B2 (en) | 2005-07-01 | 2011-08-16 | National University Corporation Okayama University | Apparatus for denaturating bilirubin and bilirubin dialyzer |
JP2009520703A (ja) * | 2005-12-23 | 2009-05-28 | ブルートシュペンデディーンスト デア ランデスフェアベンデ デス ドイチェン ローテン クロイツェス ニーダーザクセン,ザクセン−アンハルト,テューリンゲン,オルデンブルク ウント ブレーメン ゲーゲ | 給血者の血、血漿、または、赤血球濃縮物中の病原体を柔軟な容器中で動かしながら不活化するための方法 |
JP2008161095A (ja) * | 2006-12-27 | 2008-07-17 | Univ Of Tokushima | 紫外線殺菌装置と紫外線殺菌方法 |
JP2010532214A (ja) * | 2007-07-02 | 2010-10-07 | カリディアンビーシーティ バイオテクノロジーズ,エルエルシー | 測定手段を用いて血液中および血液生成物中の汚染物質を光還元するための装置 |
JP2012528873A (ja) * | 2009-06-02 | 2012-11-15 | セラムオプテック インダストリーズ インコーポレーテッド | 抗菌性光力学治療を用いたヒト血液及び血液製剤における微生物枯渇のための新たな方法 |
JP2013517093A (ja) * | 2010-01-19 | 2013-05-16 | セラモプテック インダストリーズ,インコーポレイテッド | 増強された抗菌pdt |
WO2017164202A1 (ja) * | 2016-03-23 | 2017-09-28 | テルモ株式会社 | 光照射装置 |
JPWO2017164202A1 (ja) * | 2016-03-23 | 2019-02-07 | テルモ株式会社 | 光照射装置 |
Also Published As
Publication number | Publication date |
---|---|
WO2003063915A1 (en) | 2003-08-07 |
DE60327166D1 (de) | 2009-05-28 |
JP4704684B2 (ja) | 2011-06-15 |
EP1469891A1 (en) | 2004-10-27 |
CA2474242A1 (en) | 2003-08-07 |
CA2474242C (en) | 2011-05-17 |
EP1469891B1 (en) | 2009-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6843961B2 (en) | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light | |
JP4704684B2 (ja) | 光増感剤および光のピーク波長を使用する血液および血液製剤中の汚染の減少 | |
EP1289991B1 (en) | Method for inactivation of microorganisms using photosensitizers | |
US8339592B2 (en) | Apparatus for photo reduction of contaminants in blood and blood products with calibration means | |
CA2397862C (en) | Storage solution containing photosensitizer for inactivation of biological contaminants | |
AU744978B2 (en) | Method and apparatus for inactivation of biological contaminants using photosensitizers | |
US20020015662A1 (en) | Inactivation of contaminants using photosensitizers and pulsed light | |
JP4634039B2 (ja) | 光増感剤を使用する西ナイルウイルスおよびマラリアの不活化 | |
WO2002026270A2 (en) | Inactivation of contaminants using photosensitizers and pulsed light | |
US9044523B2 (en) | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light | |
WO2001094349A1 (en) | Method and apparatus for inactivation of biological contaminants using photosensitizers | |
US20030215784A1 (en) | Method and apparatus for inactivation of biological contaminants using photosensitizers | |
JP2005523337A (ja) | 病原体が減少する血液および血液構成成分のプロセスの間でのアデニンの除去 | |
JP2004520448A (ja) | 酸化防止剤を使用するウイルスの不活性化法 | |
US20030141260A1 (en) | Oxygen-enhanced pathogen inactivation | |
US20030073650A1 (en) | Method and apparatus for inactivation of biological contaminants using photosensitizers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051220 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20071012 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091028 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100910 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110208 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110310 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4704684 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140318 Year of fee payment: 3 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140318 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |